

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/00, A01K 67/00	A1	(11) International Publication Number: WO 96/39494 (43) International Publication Date: 12 December 1996 (12.12.96)
(21) International Application Number: PCT/US96/08233 (22) International Filing Date: 31 May 1996 (31.05.96) (30) Priority Data: 08/464,961 5 June 1995 (05.06.95) US (60) Parent Application or Grant (63) Related by Continuation US 08/464,961 (CIP) Filed on 5 June 1995 (05.06.95) (71) Applicant (for all designated States except US): NEW YORK UNIVERSITY [US/US]; 550 First Avenue, New York, NY 10016 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): SUN, Tung-Tien [US/US]; 107 Edgemont Road, Scarsdale, NY 10583 (US). (74) Agents: LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, Suite 201, 210 Lake Drive East, Cherry Hill, NJ 08002 (US).		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: METHOD FOR EXPRESSION AND ISOLATION OF BIOLOGICALLY ACTIVE MOLECULES IN URINE (57) Abstract A method for the directing expression of biologically active molecules in the urothelium via use of urothelial-specific promoters and a method for producing transgenic animals resulting in the expression of biologically active molecules that are secreted into their urine for subsequent recovery are provided.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Larvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

METHOD FOR EXPRESSION AND ISOLATION OF
BIOLOGICALLY ACTIVE MOLECULES IN URINE

BACKGROUND OF THE INVENTION

Urothelium, also known as transitional epithelium, is a
5 multilayered epithelium that covers the surface of much of the
urogenital tract including the renal pelvis, ureter, the entire
bladder and a portion of the urethra. The apical surface of
urothelium, in direct contact with the urine, is covered with
numerous rigid looking plaques. These plaques cover a large
10 portion of the apical surface of mammalian urothelium. Hicks,
R.M. *J. Cell Biol.* 1965, 26, 25-48; Koss, L.G. *Lab. Invest.*
1969, 21, 154-168; Staehelin, L.A. *J. Cell Biol.* 1972, 53,
73-91. They are believed to play a crucial role as a
permeability barrier (Hicks, R.M. *Biol. Rev.* 1975, 50, 215-246)
15 and/or as physical stabilizer of the urothelial cell surface
(Staehelin, L.A. *J. Cell Biol.* 1972, 53, 73-91). When viewed
in cross section, the outer leaflet of the plaque is almost
twice as thick as the inner one, hence the term "asymmetrical
unit membrane" or "AUM" has been used to describe these
20 plaques.

It has recently been shown that AUM contain 4 major
integral membrane proteins which are called uroplakin Ia (UPIa;
28 kDa), uroplakin Ib (UPIb; ~27 kDa), uroplakin II (UPII; 15
kDa) and uroplakin III (UPIII; 47 kDa). EM-immunolocalization
25 studies established that these uroplakins are AUM-associated *in*
situ, thus establishing them as the major protein subunits of
urothelial plaques. Yu et al. *J. Cell Biol.* 1990, 111,
1207-1216; Wu et al. *J. Biol. Chem.* 1990, 265, 19170-19179.
Immunohistochemical survey of various bovine tissues
30 established that these UPs are urothelium-specific being
present in the upper cell layers of the urothelia that cover
the urogenital tract including the renal pelvis, ureter,
bladder and part of the urethra. These data established

- 2 -

uroplakins as excellent markers for an advanced stage of urothelia differentiation. Yu et al. *J. Cell Biol.* 1990, 111, 1207-1216; Wu et al. *J. Biol. Chem.* 1990, 265, 19170-19179. Furthermore, uroplakins Ia, Ib, II and III appear to be the
5 major protein components of all mammalian urothelial plaques. They are found in eight other mammalian species (human, monkey, sheep, pig, dog, rabbit, rat, and mouse), and the AUMs of these species appear morphologically similar, bearing crystalline
10 patches of 12-nm protein particles with a center-to-center spacing of 16.5 nm. Wu et al. *J. Biol. Chem.* 1994, 269, 13716-13724.

The primary structures of UPs have recently been elucidated by cDNA cloning. The results established the existence of two closely related UPI isoforms, the 27-kDa UPIa
15 and the 28-kDa UPIb. Yu, J. *J. Cell Biol.* 1994, 125, 171-182. The mRNAs of all four known UPs have recently been shown to be urothelium-specific, indicating that expression of UP genes is transcriptionally regulated. Yu, J. *J. Cell Biol.* 1994, 125, 171-182; Lin et al. *J. Biol. Chem.* 1994, 269, 1775-1784; Wu,
20 X.-R. and Sun, T.-T. *J. Cell Sci.* 1993, 106, 31-43.

The expression of the mouse UPII gene, like its bovine counterpart, is urothelium- and late-differentiation stage-specific. Using transgenic mouse techniques, a 3.6-kb 5' flanking region has now been identified as a promoter
25 comprising the cis-elements for directing the expression of a heterologous reporter gene specifically and efficiently to the suprabasal cell layers of the urothelium in a manner similar to the endogenous UPII gene. Using this promoter, it has now been found that foreign proteins can be directed to the upper cell
30 layers of the bladder urothelium for expression and secretion into urine.

SUMMARY OF THE INVENTION

An object of the present invention is to provide a method for expressing biologically active molecules in the luminal
35 cavity of the bladder of transgenic animals for subsequent excretion and recovery from urine wherein expression of the

- 3 -

gene encoding the biologically active molecule is targeted to and driven by a class of urothelial-specific promoters that drive, for example, uroplakin-related genes to express in the upper cell layers of urothelia. The sequence of the 3.6 kB upstream promoter region of mouse uroplakin II gene is provided.

Another object of the present invention is to provide a method of producing transgenic animals containing urothelial promoter-driven heterologous genes encoding biologically active molecules.

Yet another object of the present invention is to provide a method for producing a biologically active molecule which comprises producing a transgenic animal which expresses a selected biologically active molecule in bladder epithelial cells and recovering the biologically active molecule from urine produced by the transgenic animal.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is the organization and nucleotide sequence of the mouse uroplakin II (UPII) genomic DNA. Figure 1a provides the exon-intron organization of mouse UPII gene. The open and filled thick boxes denote the five coding sequences (exons) and non-coding sequences (introns), respectively, of the gene. The open and filled thin boxes represent a (CA)_n dinucleotide repeat region and an Alu-like murine B1 repeat, respectively. G1 and G2 designate two independent and partially overlapping genomic clones. The restriction sites are *Sac*I (S), *Nco*I (N), *Bam*HI (B), *Sal*I (Sal), and *Xho*I (X). Figure 1b provides the nucleotide sequence (SEQ ID NO: 1) of a 4-kb *Sac*I fragment of mouse UPII gene. A reversed B1 repetitive sequence (in the 5' upstream region) and a potential polyadenylation site (AATAAA; in the 3' untranslated region) are underlined and double-underlined, respectively. The wavy arrow denotes the transcriptional initiation site. Broken arrows marked 1 to 4 denote the intron/exon junctions of the four introns. The predicted first amino acid residue of mature UPII protein sequence is marked with an asterisk. The preceding domain

- 4 -

contains a pre and a pro sequence of 25 and 59 amino acids, respectively.

Figure 2 illustrates the tissue distribution of UPII mRNA as assayed by RT-PCR. Poly(A)⁺ mRNAs (0.3 - 0.4 mg) from mouse bladder (lanes 1 and 13), skin (2), forestomach (3), glandular stomach (4), kidney (without renal pelvis) (5), liver (6), spleen (7), testis (8), and thalamus/hypothalamus (9), cerebral cortex (10), and cerebellum (11) regions of the brain were reverse-transcribed, and amplified with either UPII-specific primers (Upper; 266 bp) or glyceraldehyde-3-phosphate dehydrogenase (GDH)-specific primers (Lower, as an internal control for comparison; 130 bp). The PCR products were then electrophoresed on a 1.3% agarose gel and stained with ethidium bromide. Lane 12 is a negative control (no cDNA template). The 266-bp UPII product was detected in abundance in bladder, but not in any other tested tissues, including the hypothalamus.

Figure 3 illustrates the construction and quantitation of a representative transgene. Figure 3a provides a restriction map (abbreviations as described in Figure 1) of the endogenous murine UPII gene. A 500-bp PCR fragment (thick bar) was used as a probe which detects a 1.4-kb *Nco*I fragment of the endogenous UPII genome but a shorter 1.1-kb *Nco*I fragment of the transgene. Figure 3b provides a restriction map of the transgene. A 3.6-kb 5'-flanking sequence of the UPII gene was inserted into an *Escherichia coli* β -galactosidase (β -gal)-encoding placF vector. In this particular test expression vector, a sequence containing a part of exon 1 and all of intron 1 and exon 2 of the mouse protamine-1 gene (mp1) was placed at the 3'-end of the β -gal (or *lacZ*) gene to provide an exon/intron splicing site and a polyadenylation signal. This chimeric gene was cut out from the vector, gel-purified, and microinjected into mouse eggs.

DETAILED DESCRIPTION OF THE INVENTION

Two major problems of producing biologically active molecules such as protein products from cloned genes on a

- 5 -

commercially viable scale are: (1) that bacterial expression systems frequently fail to modify the proteins properly, i.e., by glycosylation, etc., and (2) the subsequent isolation of gene products from the expression systems. In bacteria, yeast, and baculovirus systems the expressed proteins are most often purified from insoluble intracellular compartments. Secreted proteins in yeast require specialized protease-deficient strains coupled with appropriate vectors with secretion signals. More recently, there has been success in using mammary gland-specific promoters to drive the expression of foreign proteins in these secretory glands, ultimately leading to their secretion in the resultant milk. This method has been used commercially to express human growth hormone in cows and sheep. WO 94/05782. The copious volumes of milk produced by cows and sheep make this procedure attractive. However, this method suffers from several potential drawbacks: one being that the expressed protein even at relatively high levels must be purified away from a large amount of milk proteins such as caseins, immunoglobins, lactoferrins which may also entrap the desired valuable product; another being that certain protein products may be insoluble in the calcium-rich environment of milk fluid; and another being that this method requires the use of pregnant animals which are expensive and time consuming to produce.

In the present invention, a method has been developed for expressing biologically active molecules in the luminal cavity of the bladder of transgenic mammals. Urine in the bladder is of relatively high osmolality (50 to 1,000 mosmol/kg), with pH values as low as 4.5, and contains high concentrations of urea and ammonium. The lumen of the bladder may therefore provide an advantageous environment for the production of proteins that are normally difficult to express due to insolubility. The urea and high osmolality may serve as *in situ* denaturants and chaotropic agents. However, urine contains relatively little protein, in comparison with milk, as the kidneys are designed to prevent protein loss, therefore urothelial promoter-driven expression of proteins which by-passes the kidney produces the

- 6 -

desired protein in a solution with relatively little contaminating host endogenous proteins.

The promoter region of the uroplakin II gene has now been elucidated. Using a bovine UPII cDNA as a probe, a 16-kb mouse
5 genomic clone (G1) was isolated which contains an ~2.5-kb transcribed region that is flanked by ~3.5-kb and ~10 kb of 5'- and 3'- sequences, respectively (see Figure 1a). Alignment of the coding sequence with the UPII cDNA sequences of cattle (Lin et al. *J. Biol. Chem.* 1994, 269, 1775-1784), which are highly
10 homologous, defined the exon/intron junctions of four introns (Figure 1b). 5'-RACE (Frohman et al. *Proc. Nat'l Acad. Sci. USA* 1988, 85, 8998-9002) experiments using mouse bladder mucosal mRNA as a template established that the transcription site of the UPII gene is located at 60-bp 5'-upstream of the
15 translation initiation codon and 27-bp downstream of a putative TATA box. The 5'-upstream region contains an Alu-like B1 repetitive sequence (~830 bp) and a (CA)_n stretch (~2.1 kb). Finally, a polyadenylation signal resides ~230 bp downstream of the translation stop codon (see Figure 1b).

20 The mouse UPII gene is urothelium-specific like the bovine UPII gene. mRNAs were prepared from various mouse tissues and probed for the presence of UPII sequences by reverse transcription-polymerase chain reaction (RT-PCR) assay. A large amount of UPII product of expected size (266-bp) was
25 generated from the bladder, but not from skin, forestomach, glandular stomach, kidney, liver, spleen, testis, or the hypothalamus/thalamus cortex and cerebellum of the brain (see Figure 2).

A rabbit antiserum previously prepared against a
30 synthetic peptide corresponding to the N-terminal amino acid sequence ELVSVVDSGSG (1-11) (SEQ ID NO: 2) of mature bovine UPII (Lin et al. *J. Biol. Chem.* 1994, 269, 1775-1784) immunohistochemically stains the 15-kDa bovine UPII and localizes it to the superficial cell layers of bovine
35 urothelium. This antiserum cross-reacted well with mouse UPII, which contains an identical epitope, but migrates slightly slower at an apparent 17 kDa mass. Immunofluorescent staining

- 7 -

of frozen sections of mouse bladders showed that the UPII was associated with the all the suprabasal cell layers, suggesting that the onset of UPII gene expression in mouse was earlier than that in cattle.

5 To define the cis promoter elements for urothelial-specific expression and to demonstrate that heterologous genes can be targeted to the suprabasal urothelial cells as endogenous UPII, a transgenic mouse was constructed that contains a chimeric gene in which a lacZ reporter gene was
10 under the regulation of a 3.6-kb 5'-flanking sequence of the mouse UPII gene (Figure 3b). The DNA construct was injected into fertilized mouse eggs for transgenic mouse production. Southern blot analyses of the tail DNAs showed that the transgene was integrated into the genomes of 4 of 25 mice.
15 Three of these animals transmitted the reporter gene into their progeny. Southern blot analyses established that the genomic DNAs of these three transgenic lines, TG1, TC2, and TG3, contained roughly 40, 6, and 30 copies, respectively, of the reporter gene per diploid genome. Probing the same Southern
20 blot with the lacZ sequence showed that the transgenes of all three lines were in tandem repeats and were integrated into independent sites.

In all three mice lines, the transgene was expressed in the suprabasal cells of the bladder epithelium in an expression
25 pattern similar to the endogenous UPII gene. The staining correlated somewhat with gene dosage, as it was intense in TG1 (40 copies) but moderate in TG2 (6 copies) and TG3 (30 copies). β -galactosidase activity was only observed in the bladder and other urothelia of mice that had inherited the transgene,
30 confirming that the activity was transgene-specific. In all three transgenic mice, no β -galactosidase activity was detected in any of the non-urothelial stratified epithelia tested, including those of the skin, tongue, cornea, esophagus, and forestomach. The reporter gene product was also undetectable
35 in all other epithelia tested, including those of liver, lung, glandular stomach, small and large intestine, uterus, and

- 8 -

testis; or mesenchymal tissues, including fibroblasts, endothelial cells, spleen, and various muscle cells.

Experiments have also been performed wherein uroplakin II promoter was used to drive the expression of the
5 biologically active human growth hormone gene in the urothelium of transgenic mice. In these experiments, at least two independent founder lines showed an accumulation of a relatively high concentration of human growth hormone in mice urine (400-500 ng/ml). Blood concentrations of the hormone
10 were less than 5 ng/ml indicating that the synthesized hormone is secreted vectorially into the bladder cavity rather than into the bloodstream.

Other urothelia closely related to the epithelium of the bladder known to cover other areas of the urinary tract, such
15 as the renal pelvis of the kidney, the ureter, and the urethra and which also elaborate AUM plaques, exhibit similar expression of the transgene.

These data show that the 3.6-kb 5'-flanking sequence of the mouse UPII gene can drive both a heterologous reporter gene
20 and a gene for a biologically active molecules to express in the upper cell layers of the bladder epithelium. The lack of expression in other non-urothelial tissues indicates a high degree of tissue-specificity and demonstrates that the cis elements of this promoter region provide very tight regulatory
25 control on tissue-specific and differentiation-dependent expression of a gene placed downstream of the promoter. As these results were corroborated in independent transgenic lines with differing sites of transgene integration, they show that the inherent promoter activity is responsible for the
30 tissue-specific expression and is not due to the effect of neighboring sequences of the transgene integration sites. This tight regulation is a very desirable property of any promoter used for production of foreign protein products in host transgenic animals, as it assures correct delivery to target
35 production sites, high efficiency of expression of transduced genes, and minimizes toxic effect of aberrant expression.

While these experiments were conducted using the mouse UPII promoter, there is sufficient similarity between this gene in different species, so that similar results with the UPII promoter sequence in other animals is expected. For example, 5 the UP gene organization (Ryan et al. *Mamm. Genome* 1993, 4, 656-661), cDNA (Lin et al. *J. Biol. Chem.* 1994, 269, 1775-1784) and protein sequences, tissue patterns of expression, and morphology of AUMs are strikingly similar between the mouse and cow. The amino acid sequence of bovine and mouse UPII are 10 highly similar, sharing 84 of their 100 amino acid residues. Wu et al. *J. Biol. Chem.* 1994, 269, 13716-13724. In addition, although the onset of expression of the UPII gene is different in these two species, UPII is clearly differentiation-related in both cow and mouse bladder epithelia.

15 In the present invention, a delivery system is provided that can specifically transform the bladder into a bioreactor capable of making a transgenic product. This delivery system comprises a transgene containing a 3.6-kb 5'-flanking sequence of a urothelium-specific gene, for example, the mouse uroplakin 20 II gene, and a gene encoding a biologically active molecule. In one embodiment, this transgene is introduced into germ cells to produce a transgenic animal capable of expressing the biologically active molecule in its bladder. As used herein, "biologically active molecule" refers to a molecule capable of 25 causing some effect within an animal, not necessarily within the animal having the transgene. Examples of such molecules include, but are not limited to, adipokinin, aldosterone, adrenocorticotropin, blood clotting factors, chorionic gonadotropin, corticoliberin, corticotropin, cystic fibrosis transmembrane conductance regulators, erythropoietin, 30 folliberin, follitropin, glucagon gonadoliberin, gonadotropin, hypophysiotropic hormone, insulin, lipotropin, luteinizing hormone-releasing hormone, luteotropin, melanotropin, parathormone, parotin, prolactin, prolactoliberin, prolactostatin, somatoliberin, somatotropin, thyrotropin, 35 tissue-type plasminogen activator, and vasopressin. Of course, as will be obvious to one of skill in the art, the above list

- 10 -

is not exhaustive. In addition, new genes for biologically active molecules that will function in the context of the present invention are continually being identified. The biologically active molecule can be isolated from the urine of
5 these transgenic animals. Accordingly, the present invention provides a means for isolating large amounts of biologically active molecules from the urine of transgenic animals which can be used for a variety of different purposes.

In another embodiment, the transgene is carried in a
10 vector which is well received by the epithelial cells lining the lumen of the bladder. An example of a useful vector system is the Myogenic Vector System (Vector Therapeutics Inc. Houston Texas). In this embodiment, the transgene carried in the vector is introduced into the bladder of an animal *in vivo*.
15 Introduction of the vector can be carried by a number of different methods routine to those of skill in the art. For example, a vector of the present invention could be placed in direct contact with the urothelium via a rubber urethral catheter or Foley catheter. Vectors of the present invention
20 can also be incorporated into liposomes and introduced into the animal in that form. The transgene is absorbed into one or more epithelial cells capable of expressing and secreting the biologically active molecule into the urine collecting in the bladder. It may be preferred for some biologically active
25 molecules to also engineer a signaling sequence into the vector to insure that the molecule is secreted from the apical surface into the lumen. Use of signaling sequences such as the glycoposphatidylinositol (GPI) linkage in anchoring molecules to a selected surface is well known in the art. The
30 biologically active molecule is then voided from the lumen where it can be collected and separated from other components in the urine.

The following nonlimiting examples are provided to further illustrate the present invention.

EXAMPLES**Example 1: Characterization of the Mouse UPII Gene**

A bovine UPII cDNA (Lin et al., *J. Biol. Chem.* 1994, 269, 1775-1784) was used as a probe to screen a mouse EMBL3-SP6A/T7
5 genomic library (Clontech Laboratories Inc. Palo Alto, CA).
Two overlapping clones (G1 and G2) were isolated (Figure 1a)
and were sequenced by the dideoxynucleotide termination method.
The transcriptional initiation site was determined by
sequencing three clones of 5'-RACE (rapid amplification of cDNA
10 ends) products of mouse bladder cDNA.

Example 2: Expression of a Fusion Gene (UPII-lacZ) in Transgenic Mice

A 6-kb XhoI DNA fragment of the G1 genomic clone (Figure
1a) was subcloned in pGEM7Z and then restriction-cut to yield
15 a 3.6-kb DNA fragment of G1 clone (extending from the XhoI site
at -3.6 kb to the BamHI site at -42 bp relative to the
transcription initiation site) and inserted into the SmaI site
of a lacZ vector, placF, (Peschon et al. *Proc. Natl. Acad. Sci.*
USA 1987, 84, 5316-5319; Mercer et al. *Neuron* 1991, 7, 703-716)
20 to generate pUPII-LacZ (Figure 3). The 7.1-kb fusion gene was
excised using Kpn I and Hind III, gel-purified, and
microinjected into fertilized mouse eggs (from F1 hybrids of
C57BL/6J X DBA2), which were implanted into CD-1 foster
mothers. The lacZ transgene was identified by Southern blot
25 analysis of tail DNA in accordance with methods well known in
the art. Positive founder animals were back-crossed with
(C57BL/6J X DBA2) F1 hybrids to generate semizygous animals
that were used for studying transgene expression.

- 12 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Tung-Tien Sun
- (ii) TITLE OF INVENTION: Method for Expression and
and Isolation of Biologically Active Molecules
in Urine
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Jane Massey Licata, Esq.
 - (B) STREET: 210 Lake Drive East, Suite 201
 - (C) CITY: Cherry Hill
 - (D) STATE: NJ
 - (E) COUNTRY: USA
 - (F) ZIP: 08002
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
 - (B) COMPUTER: IBM 486
 - (C) OPERATING SYSTEM: WINDOWS FOR WORKGROUPS
 - (D) SOFTWARE: WORDPERFECT 5.1
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: not yet assigned
 - (B) FILING DATE: Herewith
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Jane Massey Licata
 - (B) REGISTRATION NUMBER: 32,257

- 13 -

(C) REFERENCE/DOCKET NUMBER: NYU-0005

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (609) 779-2400

(B) TELEFAX: (609) 779-8488

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 3963

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: No

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GAGCTCAGGT CCTATCGAGT TCACCTAGCT GAGACACCCA CGCCCCTGCA 50
GCCACTTTGC AGTGACAAGC CTGAGTCTCA GGTTCCTGCAT CTATAAAAAC 100
GAGTAGCCTT TCAGGAGGGC ATGCAGAGCC CCCTGGCCAG CGTCTAGAGG 150
AGAGGTGACT GAGTGGGGCC ATGTCACCTCG TCCATGGCTG GAGAACCTCC 200
ATCAGTCTCC CAGTTAGCCT GGGGCAGGAG AGAACCAGAG GAGCTGTGGC 250
TGCTGATTGG ATGATTTACG TACCCAATCT GTTGTCCCAG GCATCGAACC 300
CCAGAGCGAC CTGCACACAT GCCACCGCTG CCCC GCCCTC CACCTCCTCT 350
GCTCCTGGTT ACAGGATTGT TTTGTCTTGA AGGGTTTTGT TGTGCTACT 400
TTTTGCTTTG TTTTTTCTTT TTTAACATAA GGTTCCTCTG TGTAGCCCTA 450
GCTGTCCTGG AACTCACTCT GTAGACCAGG CTGGCCTCAA ACTCAGAAAT 500
CCACCTTCCT CCAAGTGCT GGGATTAAAG GCATTCGCAC CATCGCCCAG 550
CCCCCGGTCT TGTTTCCTAA GGTTTCCTG CTTTACTCGC TACCCGTTGC 600
ACAACCGCTT GCTGTCCAAG TCTGTTTGTA TCTACTCCAC CGCCCACTAG 650
CCTTGCTGGA CTGGACCTAC GTTTACCTGG AAGCCTTCAC TAACTTCCCT 700
TGTCTCCACC TTCTGGAGAA ATCTGAAGGC TCACACTGAT ACCCTCCGCT 750
TCTCCAGAG TCGCAGTTTC TTAGGCCTCA GTTAAATACC AGAATTGGAT 800

- 14 -

CTCAGGCTCT GCTATCCCCA CCCTACCTAA CCAACCCCCT CCTCTCCCAT 850
CCTTACTAGC CAAAGCCCTT TCAACCCTTG GGGCTTTTCC TACACCTACA 900
CACCAGGGCA ATTTTAGAAC TCATGGCTCT CCTAGAAAAC GCCTACCTCC 950
TTGGAGACTG ACCCTCTACA GTCCAGGAGG CAGACACTCA GACAGAGGAA 1000
CTCTGTCCTT CAGTCGCGGG AGTTCCAGAA AGAGCCATAC TCCCCTGCAG 1050
AGCTAACTAA GCTGCCAGGA CCCAGCCAGA GCATCCCCCT TTAGCCGAGG 1100
GCCAGCTCCC CAGAATGAAA AACCTGTCTG GGGCCCCTCC CTGAGGCTAC 1150
AGTCGCCAAG GGGCAAGTTG GACTGGATTC CCAGCAGCCC CTCCCACTCC 1200
GAGACAAAAT CAGCTACCCT GGGGCAGGCC TCATTGGCCC CAGGAAACCC 1250
CAGCCTGTCA GCACCTGTTC CAGGATCCAG TCCCAGCGCA GTATGGCATC 1300
CACACTGCCT GTCCAGACCT TGCCCCTGAT CCTGATTCTG CTGGCTGTCC 1350
TGGCTCCGGG GACTGCAGGT CTCTATTGCT GGTGGGTGCG AGGAGGGTTT 1400
CAGAGCGCTA GACAGGGAAC ATTGTCTCCC CAGGGCTCTC AAGGACAGGA 1450
ATGTTGGTCT AGCTGGTTGG GGTGAGAGT TACTAGTGGT AGGAATCAGG 1500
TGACAAATTC CTGGGCTTCT TCCCAGATCC AGGAGTCAAG AAATTTGGGT 1550
AAGTGTCCAA GGTTTGTGTG AGTTGGGCGA GACTGGGGAC TGACTGGGTG 1600
CCATGGTCTA GTTTGGGTCG GTAGGGCTAT CTGGCTCCCA ACAGCGCGGC 1650
GTACCCACCA TCTGCAGATC AAGCCTGCCA TCTGGTGGTC AGATCCACAC 1700
GCTCCTCTTC TGTCTCTGCA CCCTTAGCAA TGACCACCCA CCCACCCCGC 1750
CAGCTCTGAG TTAAGAGGGG GCTAACTCCT GAGTTCCCTC TCGGCTCCCT 1800
AACAGACTTC AACATCTCAA GCCTCTCTGG TCTGCTGTCT CCGGCGCTAA 1850
CAGAAAGCCT GTTAATTGCC TTGCCCCCAT GTCACCTCAC GGGAGGTAAT 1900
GCCACATTGA TGGTCCGGAG AGCCAACGAC AGCAAAGGTA GACCTCCCTT 1950
GTACCCATTT ATTCTACTCG TCGTAACCCC TCTTAACGAT ACCCAAGAGC 2000
TGCCCGTTCT ACAAGAGTGG ACGCTAGAAT CTGATCTTGC CTTTCACTCC 2050
TATTTCCCCT CAGTGGTTAA GTCAGACTTT GTGGTGCCTC CATGTCGCGG 2100
GCGCAGGGAG CTTGTGAGCG TGGTGGACAG TGGGTCTGGC TACACCGTCA 2150
CAAGGCTCAG CGCATATCAG GTGACAAACC TAACACCAGG AACCAAATAC 2200

- 15 -

TAGTAGGTAC CGATGGACAC CTGTGGAGGT GGGATGGCAA AAAAGGGAAG 2250
TGGAGGTCCC GTGAGGGTGG GGAAGTGCCG GGAAGCATGA GTTAGAGAGG 2300
GCACAGCTAA AGGGTAGGAA ATGTGAACCT GGACCCCAGG AGGGCCCAGA 2350
TGGGACACAT AGCTAGAAGG TGGAGGCTGG AACCCTCCT CCCGAGTGCC 2400
AGATACGTAC AACCTCTGCT TTCTCTCAAC TCCGCCTCTA AAGCATATCC 2450
TACCGAGTAC AGAAGGGGAC GTCGACCGAG TCCAGTCCAG AGACTCCCAT 2500
GTCCACGCTT CCTCGTTAAG TAAAATGCCC GTCTCTCACA CTTCCCTAAG 2550
CTCCGACTTT TTTCTCCTAG AGCAAGTTAG CTAAACTGTT TCCCGAGTGC 2600
TCAGTCGCAC ACACACCCCC TCCCCAACCC CCCAGTATTT GGTATGGCCC 2650
CTCCTGTCCT GTTCAATCAT CTCTGCACTA GAGGTCCTT GTGCAGAGGG 2700
ATGATGTCCT CTTGGTGGC TCCTAAGTGT TGCTGTGAGG GGGGTCTATG 2750
TTTGCTTGAC TGGTTGGCTG GATGACCAGT TGAAGTATG CTGGAGGCTA 2800
CTGGATGGCT GGGCTAATGC TGTGAACCAC AGGAGCTACC TAGGAACCCC 2850
TTCAACTCAC AGAGGTTCCC CCATCTTCTT CTGACAGGAA AAAACATGGA 2900
GTCTATTGGG TTAGGAATGG CCCGGACAGG AGGGATGGTG GTCATCACAG 2950
TGCTGCTGTC TGTGGCCATG TTCCTGTTGG TCGTGGGTCT TATTGTTGCC 3000
CTGCACTGGG ATGCCCCGAA ATGAAAAGGG CTCTCCTGCA TCCCAGGCTC 3050
CTCCAAGAAG TCCAGCCTGC CTCCTGCCAG GCTGTAGTCA CTGGCTTCTC 3100
AGTGGCTTTT CTTCCCTCTC CCCGCCCCCT CCTCGAGTCC ACTCCTGACA 3150
GTGCCCCCTC CTTGCTCCCT GTCTCACCTT GCAGCACTCC CTGCTAGCCC 3200
CACTGCAATC CTGCCAACAC TGATTTATCT CTTAACTGTA CTTAATTCTC 3250
ACAATAAAGG CTGACCCACG TAGTATGTCT CATCTCCGAC CATGTCTATG 3300
TGAGTCACCC CTTTAGCTGG TCCCCTTATG CACATATCAA AACTACCAAT 3350
GTCAAGGTCA CGTGCAATG ATTTTCTCTA TCCCAAACCC CAAGGGTGAC 3400
TTTTACCAGG AGGGAGGCAA GCAGAGGCAG AGATAATGAA GCCTCAAGCC 3450
CAGACTAGGG AAGCCCTCCA AGCCCCAGAC CTAGGGCTTG GGTTTTGCAT 3500
CCTGCACTCA GTAGATACCC AAGCAGGAGT CTAGTTGGGC AGGGGGTAGA 3550
AGCTGGATCA CCATGTGAGC CTGACTGGGA AGCTGACAGA ACTAGGGAAG 3600

- 16 -

AACTAGAGAA AACACAAACA GGGCAGGCCC TCCAGCCCTG GGTGAAGAAC 3650
ATGCTAAACG GTTCTAGACC CCTAGAGCCG AGGTGGACGG AAGCTCCTGG 3700
AAGGGGGAGG GGGGGACACA ACATAGGTAA ACAGGCAGTG GCACCCTCGT 3750
CCATTTTTTAA AATATAGTTT TGTTCTATAA AAGTTTTATT TATTTATTTA 3800
TTTGCTTGTT TTTATTTGTT TGTTTGTTTT CCAGAGCTGA GGCAAAAACC 3850
CAGGACCTTG AGCTTGCTAG GCAAGTGCTC TACCACTGAG CTAAATCCCC 3900
AAGCCCTGTT TTTGTTTTTT TGAAGCAGGG TTTCTCTGTG TAGCTCTGGC 3950
TGTCCCTAGAG CTC 3963

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11

(B) TYPE: Amino Acid

(D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

GLU	LEU	VAL	SER	VAL	VAL	ASP	SER	GLY	SER	GLY
1				5					10	

- 17 -

What is claimed is:

1. A delivery system that specifically transforms bladder epithelial cells to express a selected biologically active molecule comprising a urothelium-specific promoter sequence
5 and a gene encoding a selected biologically active molecule.
2. A method for producing a biologically active molecule comprising:
contacting bladder epithelial cells in an animal with
a vector comprising a urothelium-specific promoter sequence
10 and a gene encoding a selected biologically active molecule
so that the gene encoding a selected biologically active
molecule is expressed; and
recovering the biologically active molecule from urine
produced by the animal.
- 15 3. A method for producing a biologically active molecule
comprising:
producing a transgenic animal which expresses a
selected biologically active molecule in bladder epithelial
cells; and
20 recovering the biologically active molecule from urine
produced by the transgenic animal.

FIG. 1b-1

-1232 GAGCTCAGGTCCTATCGAGTTTCACCTAGCTGAGACACCCACGCCCTGCAGCCACTTTGCAG
TGACAAGCCCTGAGTCTCAGGTTCTGCACTATAAAAAAGAGTAGCCTTTTCAGGAGGGCATGACAGAGCCCTCGCCAGCGTCTAGAGGAG
AGGTGACTGAGTGGGGCCATGTCACTCGTCCATGGCTGGAGAACCTCCATCAGTCTCCAGTTAGCCTGGGGCAGGAGAGAAACCCAGAGGA
GCTGTGGCTGCTGATTTGGATGATTTACGTACCCAAATCTGTGTGTCCTCCAGGCATCGAATCCAGAGGCACTGCAACATGCCCACCGCTGCC
CCGCCCTCCACCTCTCTGCTCTCGGTTACAGGATGTGTGTGTCCTGAAGGGTTTGTGTGTGCTACTTTTGTGCTTTGTTTCTTTT
TAAACATAAGGTTTCTCTGTGTAGCCCTAGCTGTCTTGGAACTCACTCTGTAGACAGGCTGGCTCAAACCTCAGAAATCCACCTTTCCTCC
CAAGTGTCTGGGATTAAGGCAATTCGCAACCATCGCCACGCCCCGGGCTGTGTCTTCCCTAAGTTTCTTGTCTTACTCGCTACCCCGTTGCAC
AACCGCTTGTCTGCTCAAGTCTGTGTGTATCTACTCCACGCCCATCTGCTGGACTGGAACCTACGTTTACCTTGGAAAGCCTTTCACCTA
ACTTCCCCTTGTCTCCACCTTCTGGAGAAATCTGAAGGCTCACACTGATACCCCTCCGGCTTCTCCAGAGTCGCAGTTTCTTAGGCCCTCAGT
TAAATACCAGAAATTGGATCTCAGGCTCTGTGATCTCCCACTTACCTTAACCAACCCCTCTCTCCATCTCTTACTAGCCAAAGCCCTTTTC
AACCTTTGGGGCTTTTCTTACA CTTACACACCGGGCAATTTTGAACACTCATGGCTCTCTCTAGAAACAGCCCTACCTCTTTGGAGACTGAC
CCTCTACAGTCCAGGAGGCAGACACTCAGACAGAGGAACCTGTCTCTTTCAGTCTCGGGAGTTCCAGAAAGAGCCATACTTCCCTGCAGAG
CTAACTAAGCTGCCAGGACCCAGCCAGAGCATCCCCCTTTAGCCGAGGGCCAGCTCCCCAGAAATGAAACAACTGTCTTGGGGCCCCCTCCCT
GAGGCTACAGTCCGCCAAGGGGCAAGTTGGACTGGAAATCCAGCAGCCCTCCCACTCCGAGACAAATCAAGTACCTTGGGGCAGGCCCTC
ATTGGCCCCAGGAAACCCAGCCTGTTCAGCACCTGTTCAGGATCCAGTCCCAGCGAGTATGGCATCCACACTGCCTGTCTCCAGACCTTGT
CCCCTGATCTCTGCTGGCTGTCTGGCTCCGGGACCTGCAGGTCTCTATTTGCTGGTGGGTGCGAGGAGGTTTTCAGAGCGCTAGAG
P L I L I L A V L A P G T A DL 1
CAGGGAACATATGTCTCCCCAGGGCTCTCAAGGACAGGAATGTGTGCTTAGCTGGTTGGGGTTGAGAGTTTACTAGTGGTAGGAATCAGGTG
ACAAATCTCTGGGCTTCTTCCAGATCCAGAGTCAAGAAATTTGGGTAAAGTGTCCAAAGTTTGTGTGAGTTGGGGCAGACATGGGGACTG
ACTGGGTGCCATGGTCTAGTTTGGGTGGTAGGGCTATCTGGCTCCCAACAGCGGGCGGTACCCACCATCTGCGAGATCAAGCCCTGCCATC
TGGTGGTTCAGATCCACACGCTCCTCTCTCTGTCCTGTCACCCCTTAGCAATGACCAACCCACCCCGCCAGCTCTGAGTTAAGAGGGGCG
TAACTCTGAGTTCCCTCTCGGCTCCCTTAAACAGACTTCAACATCTCAAGCCCTCTCTGTGCTGTCTCGGGCTTAAACAGAAAGCCTGT
14J F N I S S L S G L L S P A L T E S L L
-1170
-1080
-990
-900
-810
-720
-630
-540
-450
-360
-270
-180
-90
1
91
181
271
361
451
541




FIG. 2

FIG. 3a





FIG. 3b



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/08233

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12N 15/00; A01K 67/00

US CL : 435/320.1; 800/2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/320.1; 800/2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, MEDLINE, EMBASE, BIOSIS, CAPLUS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GARVER et al. Strategy for achieving selective killing of carcinomas. Gene Therapy. 1994, Vol.1, pages 46-50, see entire document.	1
X -- Y	LIN et al. A tissue-specific promoter that can drive a foreign gene to express in the suprabasal urothelial cells of transgenic mice. Proceedings of the National Academy of Sciences. January 1995, Vol. 92, pages 679-683, see entire document.	1 ---- 2-3
Y, P	MEYER-PUTTLITZ et al. Ectopic expression of a bacterial lacZ gene in the limbic system of transgenic mice. NeuroReport. 21 August 1995, Vol.6, pages 1674-1678, see entire document.	1-3

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
I document which may throw doubts on priority claims or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

18 JULY 1996

Date of mailing of the international search report

16 AUG 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

D. CURTIS HOGUE, JR.

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/US96/08233

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BOYD et al. Review: Molecular Biology of Transgenic Animals. Journal of Animal Science. 1993, Vol. 71, Suppl. 3, pages 1-9, see entire document.	1-3